Standing Order
Madrigal Pharmaceuticals, Inc.

Dashboard

Madrigal Pharmaceuticals, Inc.

MDGLNASDAQ

For informational purposes only. Not financial advice, not a recommendation to buy or sell any security. Standing Order is a directory and research project, not an advisory service.

Universal block

Live market data + trailing fundamentals.

Market cap$12B
Price$513.0252w $272.67 – $602.83
Conviction4/ 5
Revenue (TTM)$1.3B
Revenue growth YoY+149.0%
P/E (trailing)—
Gross margin91.5%
Operating margin-25.1%
Net margin-25.3%
52w price change+88.1%
Next earningsNov 3, 2026

Recent events

Material filings, federal awards, and regulatory activity. Impact is scored against market cap.

  • Sep 21
    Trial initiationClinicalTrials.gov

    Phase 1 trial initiation of resmetirom in MASH patients with HFpEF (NCT07830758, not yet recruiting)

  • Sep 11
    Ownership changeSEC

    Form 4 insider transaction filing dated 2026-09-11.

  • Sep 11
    Trial initiationClinicalTrials.gov

    Madrigal initiates Phase 2 trial of resmetirom in children and adolescents with MASH (NCT07763015, recruiting).

  • Aug 26
    Trial initiationClinicalTrials.gov

    Madrigal initiates Phase 2 trial of resmetirom in post-liver transplant MASH patients (NCT07335601, recruiting).

  • Aug 20
    Ownership changeSEC

    Form 4 filing for insider transaction at Madrigal Pharmaceuticals.

  • Aug 18
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Aug 13
    Trial initiationClinicalTrials.gov

    Madrigal initiates Phase 2 trial of resmetirom in children and adolescents with MASH (NCT07763015), status not yet recruiting.

  • Aug 12
    LeadershipSEC

    8-K filed with items 5.02, 7.01, 9.01 covering officer/director changes and related disclosures.

  • Jul 31
    Trial initiationClinicalTrials.gov

    Madrigal initiates Phase 2 trial (NCT07335601) of resmetirom in post-liver transplant MASH patients; status recruiting.

  • Jul 30
    Financial resultsSEC

    8-K filing (items 2.02, 9.01) reporting results of operations and financial condition.

  • Jul 20
    Ownership changeSEC

    Form 4 insider transaction filing

  • Jul 8
    OtherClinicalTrials.gov

    Phase 3 MAESTRO-NASH-OUTCOMES trial (NCT05500222) for resmetirom in NASH cirrhosis status updated to ACTIVE_NOT_RECRUITING.

  • Jun 18
    Ownership changeSEC

    Form 4 insider transaction filing for MDGL.

  • Jun 18
    Ownership changeSEC

    Form 4 insider transaction filing

  • Jun 18
    Ownership changeSEC

    SEC Form 4 insider transaction filing.

  • Jun 18
    Ownership changeSEC

    SEC Form 4 insider transaction filing

  • Jun 18
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jun 18
    Ownership changeSEC

    Form 4 insider transaction filing.

  • Jun 17
    LeadershipSEC

    8-K filed disclosing items 5.02 (officer/director matters), 5.07 (shareholder vote), 9.01 (exhibits).

  • Jun 16
    Trial initiationClinicalTrials.gov

    Madrigal initiates Phase 2 trial of resmetirom in post-liver transplant MASH patients (NCT07335601, recruiting).

Not financial advice — research and opinion only. Disclosures